Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with ...
-- Casimersen is designed for the treatment of exon 45 amenable patients, approximately eight percent of patients with Duchenne -- -- Casimersen is the third exon-skipping medicine using the Company’s proprietary PMO RNA-based platform -- CAMBRIDGE, Mass …